Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases. Located in Cambridge, Massachusetts, Ataxion was founded in April 2013 out of the Atlas Venture seed program by Dr. Josh Resnick and Atlas Venture Development Corporation Managing Director and Ataxion Board Member David Grayzel, MD.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/18/14 | $17,000,000 | Series A |
Atlas Venture Biogen Idec | undisclosed |
